The incidence of liver cancer in China accounts for almost 50% of the world, and liver cancer is one of the main focuses of tumor prevention in China, with 400,000 new liver cancer patients each year, accounting for about 25.0% of the total tumor patients in China. Liver cancer is the third most common malignant tumor in China, and the most effective treatment method for early stage liver cancer is surgery. However, more than 80% of patients lose the opportunity of surgical resection when they are diagnosed. For these patients with middle and late stage liver cancer who cannot be surgically resected, minimally invasive treatment is mainly used, which can still achieve definite curative effect. One is vascular minimally invasive treatment, also known as interventional treatment, including hepatic artery infusion chemotherapy (TAI), hepatic artery embolization (TAE) and hepatic artery embolization chemotherapy (TACE); the other is non-vascular minimally invasive treatment, including percutaneous chemical ablation and percutaneous physical ablation, the former commonly used are percutaneous anhydrous alcohol-free injection (PEI), percutaneous puncture The former includes percutaneous anhydrous alcohol-free injection (PEI), percutaneous puncture and acetic acid injection, while the latter includes argon helium supercooled knife freezing, radiofrequency ablation (RFA), microwave coagulation (MCT), laser interstitial thermotherapy and high intensity focused ultrasound. Among them, argon helium supercooled knife freezing, radiofrequency ablation (RFA) and microwave coagulation (MCT) are being more and more widely used in clinical practice. Argon-helium cryosurgery kills cancer cells by ultra-low temperature (-140℃ or so) and has a thermal therapy effect. Radiofrequency ablation and microwave coagulation belong to the category of thermal ablation, which both kill cancer cells through high temperature. Ning Houfa, Department of Interventional Radiology, Affiliated Hospital of Weifang Medical College The study of Keio University School of Medicine in Japan proved that the ablation rate of argon-helium supercooled knife treatment for liver cancer reached 96.5%. The results of the experimental study showed that Ar-He knife cryotherapy was superior to radiofrequency ablation and microwave coagulation therapy in terms of reducing tumor residual and metastasis, and prolonging the survival of experimental rabbits. In particular, during the process of radiofrequency ablation and microwave coagulation, there is a “boiling effect” that predisposes to peritoneal implantation metastasis via the needle tract. For giant or multiple intermediate and advanced hepatocellular carcinoma, interventional therapy is a more effective treatment method. Argon helium ultracold knife combined with interventional therapy for giant or multiple intermediate and advanced hepatocellular carcinoma can significantly improve patients’ survival time and reduce recurrence rate. It has developed into the preferred treatment option for middle and late stage liver cancer. Recognition of Ar-He Supercooled Knife for Liver Cancer by International Interventional Community At the 91st Annual Meeting of RSNA in Chicago in November 2005, the effectiveness of Ar-He Supercooled Knife in a wide range of treatment areas such as liver cancer, lung cancer, prostate cancer, kidney tumor, bone tumor and pelvic tumor was recognized. The fact that 12 radiology and interventional authorities from the top international oncology centers chose the Ar-He supercooled knife for treatment and conducted in-depth studies proves that the Ar-He supercooled knife is being widely accepted by the oncology community and patients, and that it will become a new choice for cancer treatment.